comparemela.com

Latest Breaking News On - Sunshine guojian pharmaceutical - Page 3 : comparemela.com

DelveInsight Business Research, LLP: Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain

Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This

United kingdomEvelo biosciencesDennis riedlShruti thakurKeymed biosciencesVerona pharmaLanier biotherapeuticsArchivel farmaChiesi farmaceuticiBudesonide formoterolAstrazeneca airsupraSanders morris harrisSterna biologicsEvelo biosciences incUniversity collaborations licensing partnering analysisTherapeutics assessmentby route of administration

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

/PRNewswire/ HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today.

Jing louUnited statesSteven dasong wangZhenping zhuResearch at imclone systemsSunshine guojian pharmaceutical shanghai co ltdSbio groupKadmon holdingsBio therapeuticsHankang capitalYonghua investmentSunshine guojian pharmaceuticalChief executive officerChief scientific officerExecutive vice presidentVice president

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

/PRNewswire/ HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today.

Jing louUnited statesSteven dasong wangZhenping zhuResearch at imclone systemsSunshine guojian pharmaceutical shanghai co ltdSbio groupKadmon holdingsBio therapeuticsHankang capitalYonghua investmentSunshine guojian pharmaceuticalChief executive officerChief scientific officerExecutive vice presidentVice president

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Jing louUnited statesSteven dasong wangZhenping zhuResearch at imclone systemsSunshine guojian pharmaceutical shanghai co ltdSbio groupKadmon holdingsBio therapeuticsHankang capitalYonghua investmentSunshine guojian pharmaceuticalChief executive officerChief scientific officerExecutive vice presidentVice president

Numab Therapeutics AG: Numab and 3SBio s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option

Hong kongJing louMacau generalDavid urechMadeline davidshoferSunshine guojian pharmaceutical shanghai co ltd3sbio incNumab therapeuticsSunshine guojian pharmaceuticalSunshine guojianGreater chinaChief executive officerSerum albuminExecutive officerDougall advisors

vimarsana © 2020. All Rights Reserved.